PhaseBio Pharmaceuticals Capex per Share

Capex per Share of PHAS for past 10 years: annual, quarterly and twelve month trailing (TTM) including Capex per Share growth rates and interactive chart. Capex per share refers to the total amount of capital expenditures paid in a period divided by the weighted average number of shares outstanding. If a company has capex of $100 million and 10 million shares outstanding, capex per share is $10.


Highlights and Quick Summary

  • Capex per Share for the quarter ending September 29, 2021 was -0.01 (a 150.94% increase compared to previous quarter)
  • Year-over-year quarterly Capex per Share increased by 600.0%
  • Annual Capex per Share for 2020 was -0.05 (a 39.26% increase from previous year)
  • Annual Capex per Share for 2019 was -0.03 (a 55.8% increase from previous year)
  • Annual Capex per Share for 2018 was -0.02 (a 160.47% increase from previous year)
  • Twelve month Capex per Share ending September 29, 2021 was -0.02 (a 73.64% increase compared to previous quarter)
  • Twelve month trailing Capex per Share decreased by -53.33% year-over-year
Trailing Capex per Share for the last four month:
29 Sep '21 29 Jun '21 30 Mar '21 30 Dec '20
-0.02 -0.01 -0.03 -0.05
Visit stockrow.com/PHAS for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Capex per Share of PhaseBio Pharmaceuticals

Most recent Capex per Shareof PHAS including historical data for past 10 years.

Interactive Chart of Capex per Share of PhaseBio Pharmaceuticals

PhaseBio Pharmaceuticals Capex per Share for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 -0.01 -0.01 -0.0
2020 -0.0 -0.01 -0.02 -0.02 -0.05
2019 -0.0 -0.01 -0.01 -0.0 -0.03
2018 -0.02 -0.0 -0.03 -0.01 -0.02
2017 0.0 -0.27 -0.01
2016 0.0

Business Profile of PhaseBio Pharmaceuticals

Sector: Healthcare
Industry: Biotechnology
PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiopulmonary diseases. Its lead product candidate is bentracimab (PB2452), a reversal agent for the antiplatelet drug ticagrelor that is in Phase III clinical trial for patients with uncontrolled major or life-threatening bleeding events or in patients requiring urgent or emergency surgery. The company is also developing PB1046, a vasoactive intestinal peptide analogue that is in Phase IIb clinical trial for the treatment of pulmonary arterial hypertension; and PB6440 for the treatment of resistant hypertension. The company has a co-development agreement with SFJ Pharmaceuticals X, Ltd. to develop PB2452, a reversal agent for the antiplatelet drug ticagrelor. PhaseBio Pharmaceuticals, Inc. was incorporated in 2002 and is based in Malvern, Pennsylvania.